Gemini Therapeutics, Inc. GMTX
We take great care to ensure that the data presented and summarized in this overview for Gemini Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GMTX
View allLatest Institutional Activity in GMTX
Top Purchases
Top Sells
About GMTX
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at GMTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2025
|
Rahul Khara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,161
-3.0%
|
$62,694
$54.58 P/Share
|
|
Feb 18
2025
|
Pamela Stephenson Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
3,137
-4.32%
|
$169,398
$54.58 P/Share
|
|
Feb 18
2025
|
Jean M. Franchi Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,136
-4.32%
|
$169,344
$54.58 P/Share
|
|
Feb 18
2025
|
Jonathan Yen Wen Yu Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,610
-3.82%
|
$86,940
$54.58 P/Share
|
|
Feb 18
2025
|
William Jacob Savage Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,638
-2.34%
|
$88,452
$54.58 P/Share
|
|
Feb 18
2025
|
John D Quisel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
5,574
-3.48%
|
$300,996
$54.58 P/Share
|
|
Feb 10
2025
|
Pamela Stephenson Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+33.13%
|
-
|
|
Feb 10
2025
|
Jonathan Yen Wen Yu Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+36.27%
|
-
|
|
Feb 10
2025
|
Rahul Khara Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+38.69%
|
-
|
|
Feb 10
2025
|
John D Quisel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
78,337
+32.81%
|
-
|
|
Feb 10
2025
|
Jean M. Franchi Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,000
+33.13%
|
-
|
|
Feb 10
2025
|
William Jacob Savage Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
24,000
+25.5%
|
-
|
|
Feb 03
2025
|
William Jacob Savage Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,731
+5.9%
|
$11,462
$2.65 P/Share
|
|
Feb 03
2025
|
Rahul Khara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,500
-18.92%
|
$412,500
$55.71 P/Share
|
|
Feb 03
2025
|
Rahul Khara Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+25.83%
|
$105,000
$14.69 P/Share
|
|
Jan 02
2025
|
Rahul Khara Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
7,500
-13.19%
|
$472,500
$63.01 P/Share
|
|
Jan 02
2025
|
Rahul Khara Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+25.83%
|
$105,000
$14.69 P/Share
|
|
Dec 31
2024
|
John D Quisel Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+10.86%
|
$10,000
$1.01 P/Share
|
|
Dec 30
2024
|
John D Quisel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,012
-7.81%
|
$806,744
$62.14 P/Share
|
|
Dec 30
2024
|
John D Quisel Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,012
+13.27%
|
$117,108
$9.86 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 389K shares |
|---|---|
| Grant, award, or other acquisition | 676K shares |
| Exercise of conversion of derivative security | 141K shares |
| Open market or private sale | 146K shares |
|---|